ATLAS NANOTECH - CSSI OTC

SERIOUS INVESTORS

Medical Device - Nanotechnologies

Atlas is a leader in today’s medical nanotechnology field, with an extensive pipeline of commercially viable products.

Serious investors should place these shares on their BUY LIST 
Atlas Nanotech  Business Plan 



What Is Nanotechnology - Nova Video  -  Nanotech Robots From DNA At Cal Tech

Atlas Nanotech Opens First Revenue Stream

GUADALAJARA, Mexico, July 31, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – OTC CSSI (Costas Inc.), DBA Atlas Nanotech, today memorialized an agreement with Laboratorios Gem S.A. de C.V. of Mexico City gemlabs.mx.

The contract calls for Atlas to sell stabilized and functionalized silver nanoparticles to Gem Labs for use in the manufacture of one of Gem Labs proprietary products. This agreement represents an initial source of income for Atlas with revenue anticipated as soon as Q3 2019.

How Nanotechnology Will Change Your Life

The contract is understood as a first act of trade between the parties and goes on to define initial terms of a licensing agreement for the use and exploitation of Nanogasa (nanogasa.com), a patented development of Atlas Nanotech.

Professor David de la Mora, Atlas chairman, stated, “the production for sale of raw nanotechnology material is a growing industry,” adding, “the acceptance by Gem Labs of our nano material shows that we can produce a stable quality product at a competitive price.”

Gem Labs President Ivan Lopez stated that several other firms had been considered for the contract, however based on a sample provided by Atlas, it was the nano particles produced by Atlas that met the highest standards sought after by Gem Labs for its products.

Dr. Julio César Riestra, CEO of Atlas, said while it is important for Atlas to begin receiving these revenues from the sale of raw nanoparticles, it is of greater consequence for the firms to form a relationship and alliance; in particular, with a company of such stature as Gem Labs. There are many synergies that the two companies can exploit going forward, he said.

About COSTAS Inc. DBA Atlas Nanotech

Costas Inc. has been trading under the symbol CSSI since the year 2014.  With the recent acquisition of the Guadalajara-based nano-medical firm Atlas Nanotech, it now enters the new dynamic market of nanotechnology development and manufacturing.


Atlas Nanotech Announces The Successful Development Of The First ‘Over
The Counter’ Vitamin ‘A’ (Retinol) Eye Drops

GUADALAJARA, México--August 12, 2019 (GLOBE NEWSWIRE) – vía OTC PR WIRE --
Costas Inc. (OTC: CSSI), DBA Atlas Nanotech today announced the completion of development
of the first ever nano particle Vitamin A (Retinol) based crystalline eye drop. The product to be
sold under the trade name “NANO CLEAR A” will compete with products in the treatment of
dry eye disease a 1.8-billion-dollar market in the U.S. Dry eye syndrome is caused by a chronic
lack of sufficient lubrication and wetting on the surface of the eye.

The development represents the culmination of research initiated by Dr. Aldo Oregon Miranda
an ophthalmologist surgeon and member of the scientific advisory board of Atlas Nanotech, in
collaboration with Professor David De La Mora Atlas’ chairman.

There is currently no ophthalmic treatment based on Vitamin A that helps treat the
consequences of dry eye syndrome, which, in addition to being friendly to the eyes, has an
effectiveness greater than 5% adsorption by that organ.

However, using nanotechnology it is possible to encapsulate Vitamin A in order to achieve a
better absorption of it in the eye. Atlas has created nanoparticles of Vitamin A of less than 100
nanometers capable of being contained in a crystalline ophthalmic solution and easily
absorbed. These nanoparticles have no risk of toxicity because the concentration is very low
but much more efficient due to their size. This solves a fairly common problem in the
population that is also effective in post-surgery patients.

Dry eye disease main consequences are epithelium loss and altered tear film osmolarity that is
why Vitamin A can aid not only symptoms like any regular artificial tears product but also the
altered morphology giving long term results.

Within ophthalmology Vitamin A (Retinol) is used as corneal protector and corneal wound
healing promotor, this is possible because it has hydrophobic properties that help the epithelium
and stroma growth and also in a secondary manner to enrich the tear film composition and
osmolality.

Until now retinol could only be delivered in a suave making it useful only for sleep time use.
Also Vitamin A which is known to be the most effective treatment for post-surgical eye
procedures can in large doses can be toxic. In its particulate state retinol suspended in a
crystalline solution is completely safe for sale as an over the counter treatment.
Nano molecules allows it to remain hydrophobic which warrants better adhesion and availability
of the components. It also gives the opportunity to have a pharmaceutical form of solution and its
carried on an acetate vehicle but the fact that it is an acetate helps the permanence of the
components within the cornea.

Atlas Nanotech is currently analyzing the possibilities for production and distribution of Nano
Clear ‘A’ or a licensing of the patented process.

About COSTAS Inc. DBA Atlas Nanotech

Costas Inc. has been trading under the symbol CSSI since the year 2014. With the recent
acquisition of the Guadalajara-based nano-medical firm Atlas Nanotech, it now enters the new
dynamic market of nanotechnology development and manufacturing.

FORWARD LOOKING STATEMENTS:
This press release and the statements of representatives of Costas, Inc. (the "Company") related
thereto contain, or may contain, among other things, "forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than
statements of historical fact included herein are “forward-looking statements,” including any
other statements of non-historical information. These forward-looking statements are subject to
significant known and unknown risks and uncertainties and are often identified by the use of
forward-looking terminology such as "guidance," "projects," "may," "could," "would," "should,
“believes,” “expects," "anticipates,” “estimates," "intends," "plans," "ultimately" or similar
expressions. All forward-looking statements involve material assumptions, risks and
uncertainties, and the expectations contained in such statements may prove to be incorrect.
Investors should not place undue reliance on these forward-looking statements, which speak only
as of the date of this press release. The Company’s actual results (including, without limitation,
Costas’ ability to advance its business, generate revenue and profit and operate as a public
company) could differ materially from those stated or anticipated in these forward-looking
statements as a result of a variety of factors, including factors and risks discussed in the
periodic reports that the Company files with OTC Markets (Pink Sheets). All
forward-looking statements attributable to the Company or persons acting on its behalf are
expressly qualified in their entirety by these factors. The Company undertakes no duty to update
these forward-looking statements except as required by law.